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http://dx.doi.org/10.1016/j.chembiol.2012.09.007Signal transducer and activator of tran-
scription (STAT)3 has been found to be
persistently tyrosine phosphorylated in
a large proportion of human malignan-
cies, and has been identified as a prime
target for anticancer therapy. In 2006 we
published the discovery of Stattic, the first
small molecule shown to inhibit the func-
tion of the STAT3 SH2 domain indepen-
dent of the tyrosine-phosphorylation state
of STAT3 (Schust et al., 2006). Stattic was
shown to inhibit STAT3 activation, dimer-
ization, and nuclear translocation in
response to interleukin (IL)-6, but not
that of the closely related STAT1 (78%
similar on the protein level in the SH2
domain) in response to interferon (IFN)g.
We used HepG2 cells to demonstrate
selective inhibition of STAT3 phosphory-
lation and nuclear translocation. We also
found that Stattic increases the apoptotic
rate of breast cancer cell lines in a STAT3-
dependent manner, supporting the idea
that cancer drugs targeting the SH2
domain of STAT3 could be feasible. Since
our original publication, a large number of
independent studies have been published
by other groups that confirm the potency
of Stattic as a STAT3 inhibitor and support
its utility in combating tumor cells. These
studies demonstrate the potent anti-
cancer activities of Stattic, including
activity against colon cancer-initiating
cells (Lin et al., 2011), against glioma cell
migration on three-dimensional nanofiber
scaffolds (Agudelo-Garcia et al., 2011),
and against outgrowth of breast cancer
cells in an ex vivo model (Katz et al.,
2012), and extend to in vivo activity of
Stattic in a mouse xenograft model for
head and neck squamous cell carcinoma
(Adachi et al., 2012).
In their Letter to the Editor, ‘‘Revisiting
the specificity of small-molecule inhibi-
tors: the example of Stattic in dendritic
cells,’’ Sanseverino et al. (2012) remind
us of the possibility that the observedeffects of a compound may depend on
the cell type and the exact experimental
conditions used. In addition, they propose
studying the impact of inhibitors directed
against anticancer targets on the micro-
environment surrounding a tumor in situ.
Sanseverino et al. used human mono-
cyte-derived dendritic cells (MDDCs)
and found that Stattic inhibits not only
STAT3 activation but also activation of
STAT1 and to a lesser extent of STAT2,
which had not been tested for in the orig-
inal study (Schust et al., 2006), in
response to cell activation by IL-6 or
IFNb. An inhibitory effect of Stattic on
STAT1 phosphorylation has also been
described in human ovarian cancer cells
(Debnath et al., 2012) andmelanoma cells
(Bill et al., 2010). Thus, the effect of Stattic
on STAT1 activation appears to depend
on the cell type and the particular cytokine
used, given that we observed that IFNg-
induced STAT1 phosphorylation was not
significantly reduced by Stattic in HepG2
liver carcinoma cells (Schust et al., 2006).
The inhibitory effect of Stattic on STAT1
phosphorylation inMDDCs,ovariancancer
cells, and melanoma cells does not come
as a complete surprise, given that we
already reported an inhibitory effect of
Stattic on the STAT1 SH2 domain in vitro
in our original publication (Schust et al.,
2006). In Figure 2D of the original publica-
tion (Schust etal., 2006),Statticwasshown
to inhibit binding of a high-affinity peptide
to theSH2domainofSTAT1 toa significant
extent. Interpretation of these data was
difficult, because the activity of the irre-
versible inhibitor Stattic is temperature
dependent (Figure 2B in Schust et al.,
2006). The specificity data were generated
at 30C, not at the physiologically relevant
temperature of 37C, owing to the insta-
bility of the STAT1 (and STAT5b) protein
constructs at 37C. Therefore, it is unclear
whether the higher selectivity of Stattic for
STAT3 over STAT1 observed in our STATChemistry & Biology 19, October 26, 2012 ªdimerization and DNA binding assay
(Figure 3 in Schust et al., 2006) and the
STAT activation assays in HepG2 cells
(Figure 4 in Schust et al., 2006) reflects
a more favorable specificity profile at
37C or whether it results frommore favor-
able circumstances in the respective assay
systems, both of which provide a less
direct readout than the fluorescence polar-
ization-based binding assay (Figure 2 in
Schust et al., 2006).Given the knowneffect
of Stattic on STAT1, it seems plausible that
the variability in the relative specificities of
Stattic for STAT3 versus STAT1 observed
in the cellular assays carried out by us
and others can, at least in part, be ex-
plained by secondary signaling effects,
which vary under different experimental
conditions. Reducing the activity of one
signaling molecule affects the entire
balance of signaling in the cell, limiting our
ability to reliably predict what will happen
in a particular cell type and under varying
assay conditions.
Furthermore, Sanseverino et al. found
that treatment with Stattic reduced IL-12
protein levels in lipopolysaccharide
(LPS)-induced MDDCs. IL-12 production
is important for activation of an antitumor
Th1 T cell response, which would help the
host’s immune system to fight the tumor
cells. Cells depleted in STAT3 by RNAi
(Kortylewski et al., 2009) or lacking
STAT3 entirely due to genetic deletion
(Iwata-Kajihara et al., 2011) show an upre-
gulation of IL-12; from this, the authors
conclude that a functional inhibitor of the
STAT3 SH2 domain should do the same.
This logic, however, is an oversimplifica-
tion, because these nucleic acid-based
technologies remove the entire multido-
main protein whereas a small molecule
only interferes with the function of the
protein domain that it targets. Numerous
examples exist in the literature in which
specific inhibition of a protein domain by
a small molecule does not result in the2012 Elsevier Ltd All rights reserved 1215
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Correspondencesame outcome as removal of the entire
protein by RNA interference or genetic
knockout (Knight and Shokat, 2007;
Weiss et al., 2007). Therefore, it is
possible that inhibition of IL-12 induction
is exactly what an agent specifically tar-
geting the function of the STAT3 SH2
domain should do. An appropriate refer-
ence standard for this could be a phos-
phatase-stable, peptidase-stable, and
cell-permeable peptide mimetic shown
to target solely the STAT3 SH2 domain.
The logical connection between the effect
of Stattic on STAT1 phosphorylation as
described in the first part of the letter
(Figures 1A–1C in Sanseverino et al.,
2012) and the effect of Stattic on LPS-
induced IL-12 production (Figure 1D in
Sanseverino et al., 2012) also remains
unclear, because the recent literature
does not indicate inhibition of STAT1
phosphorylation as a general molecular
cause of reduced protein levels of IL-12.
Sanseverino et al. (2012) remind us
that the ideal cancer drug will not only
target a signaling protein of particular
relevance in a tumor but also leave intact
the body’s own defense mechanisms1216 Chemistry & Biology 19, October 26, 20against cancer. Their conclusion that we
should evaluate promising small-mole-
cule inhibitors in a wide range of preclin-
ical models before approaching clinical
trials is certainly justified. However, these
studiesmust involve comprehensive anal-
ysis of a compound’s effect on the func-
tionality of all immune cells in the tumor
microenvironment in order for us to draw
meaningful conclusions about the extent
and significance of potential adverse
effects on the body’s antitumor response.ACKNOWLEDGMENTS
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